The effectiveness of PD-L1 immunohistochemistry (IHC) in circulating tumor cells from patients with advanced lung cancer: a pilot study.
- Conditions
- Neoplasms
- Registration Number
- KCT0006282
- Lead Sponsor
- CytoGen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
1) Male and female adults over 19 years old.
2) Lung cancer group : Inoperable non-small cell lung cancer and small cell lung cancer patients who were diagnosed histologically.
3) respiratory infection group : Patients with respiratory infections such as pneumonia, tuberculosis, and non-tuberculosis mycobacteria were confirmed by microbial tests and radiation.
1) Male and female adults 19 years of age or older
2) Lung cancer group: Histologically diagnosed inoperable non-small cell lung cancer and small cell lung cancer.
3) Respiratory infection group: Patients with confirmed respiratory infections such as pneumonia, tuberculosis, and non-tuberculous mycobacterium by microbiological examination and radiographic findings.
4) Patients who can comply with the procedure according to this clinical trial protocol and who voluntarily signed the consent form
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PD-L1 Expression Rates
- Secondary Outcome Measures
Name Time Method the presence or absence of false positives cells; the level of CEA;PD-L1 Expression Rates